Global Campylobacter Diagnostics Market

Campylobacter Diagnostics Comprehensive Study by Type (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Hospitals, Private Laboratories, Independent Physician Chambers, Others) Players and Region - Global Market Outlook to 2027

Campylobacter Diagnostics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Campylobacter infection is an abnormality observed in the digestive system caused by campylobacter bacteria. Major symptoms of campylobacter infection include diarrhea, blood and mucus in stool, malaise, severe abdominal pain, nausea, fever, vomiting, and headache. The most common sources of Campylobacter infection are unpasteurized milk, raw poultry, or uncooked vegetables. Campylobacter infection is diagnosed through laboratory tests of stool, body fluids, or tissue.

Highlights from Campylobacter Diagnostics Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The key Players profiled in the report are Becton, Dickinson and Company (United States), Meridian Bioscience, Inc. (United States), Thermo Fisher Scientific (United States), BIOTECON Diagnostics (Germany), Agilent Technologies (United States), Alere Inc. (United States), QIAGEN (Germany), Roche Molecular Systems, Inc. (United States), Siemens Healthineers (Germany), Lonza (Switzerland), ZeptoMetrix (United States) and Sequenom (United States).

Geographic Breakdown and Segment Analysis
The Global Campylobacter Diagnostics market presents a comprehensive analysis of the Campylobacter Diagnostics market by product type (Culture-based Diagnosis and Rapid Detection Tests (Immunological, Molecular, and Other )), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Campylobacter Diagnostics industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Campylobacter Diagnostics market

Analyst at AMA have segmented the market study of Global Campylobacter Diagnostics market by Type, Application and Region.

Influencing Trend:
Growing Clinical Research Studies for Campylobacter Diagnosis

Market Growth Drivers:
Rising Number of People Affected with Campylobacter Infection and Increasing Geriatric Population Globally

Challenges:
Low Awareness about Campylobacter Infection Diagnosis

Restraints:
Unfavorable Medical Reimbursements

Opportunities:
Increasing Research and Development Activities Focused on Campylobacter and Rising Purchasing Power of Developing Countries

In October 2022, Thermo Fisher Scientific launched CE-IVD marked panel and to detect most common gastrointestinal bacteria. The TaqPath Enteric Bacterial Select Panel panel is based on real-time polymerase chain reaction technology and is designed to identify bacteria that cause infections such as gastroenteritis, diarrhea, and meningitis. It is expected to improve clinical decision-making and help in the early detection and prevention of outbreaks.



The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Campylobacter Diagnostics Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Culture-based Diagnosis
  • Rapid Detection Tests (Immunological, Molecular, and Other )
By End User
  • Hospitals
  • Private Laboratories
  • Independent Physician Chambers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of People Affected with Campylobacter Infection
      • 3.2.2. Increasing Geriatric Population Globally
    • 3.3. Market Challenges
      • 3.3.1. Low Awareness about Campylobacter Infection Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Growing Clinical Research Studies for Campylobacter Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Campylobacter Diagnostics, by Type, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Campylobacter Diagnostics (Value)
      • 5.2.1. Global Campylobacter Diagnostics by: Type (Value)
        • 5.2.1.1. Culture-based Diagnosis
        • 5.2.1.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 5.2.2. Global Campylobacter Diagnostics by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Private Laboratories
        • 5.2.2.3. Independent Physician Chambers
        • 5.2.2.4. Others
      • 5.2.3. Global Campylobacter Diagnostics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Campylobacter Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton, Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Meridian Bioscience, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BIOTECON Diagnostics (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alere Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. QIAGEN (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Molecular Systems, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens Healthineers (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lonza (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ZeptoMetrix (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sequenom (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Campylobacter Diagnostics Sale, by Type, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Campylobacter Diagnostics (Value)
      • 7.2.1. Global Campylobacter Diagnostics by: Type (Value)
        • 7.2.1.1. Culture-based Diagnosis
        • 7.2.1.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 7.2.2. Global Campylobacter Diagnostics by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Private Laboratories
        • 7.2.2.3. Independent Physician Chambers
        • 7.2.2.4. Others
      • 7.2.3. Global Campylobacter Diagnostics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Campylobacter Diagnostics: by Type(USD Million)
  • Table 2. Campylobacter Diagnostics Culture-based Diagnosis , by Region USD Million (2016-2021)
  • Table 3. Campylobacter Diagnostics Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2016-2021)
  • Table 4. Campylobacter Diagnostics: by End User(USD Million)
  • Table 5. Campylobacter Diagnostics Hospitals , by Region USD Million (2016-2021)
  • Table 6. Campylobacter Diagnostics Private Laboratories , by Region USD Million (2016-2021)
  • Table 7. Campylobacter Diagnostics Independent Physician Chambers , by Region USD Million (2016-2021)
  • Table 8. Campylobacter Diagnostics Others , by Region USD Million (2016-2021)
  • Table 9. South America Campylobacter Diagnostics, by Country USD Million (2016-2021)
  • Table 10. South America Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 11. South America Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 12. Brazil Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 13. Brazil Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 14. Argentina Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 15. Argentina Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 16. Rest of South America Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 17. Rest of South America Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 18. Asia Pacific Campylobacter Diagnostics, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 21. China Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 22. China Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 23. Japan Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 24. Japan Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 25. India Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 26. India Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 27. South Korea Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 28. South Korea Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 29. Taiwan Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 30. Taiwan Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 31. Australia Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 32. Australia Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 35. Europe Campylobacter Diagnostics, by Country USD Million (2016-2021)
  • Table 36. Europe Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 37. Europe Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 38. Germany Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 39. Germany Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 40. France Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 41. France Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 42. Italy Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 43. Italy Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 44. United Kingdom Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 45. United Kingdom Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 46. Netherlands Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 47. Netherlands Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 48. Rest of Europe Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 49. Rest of Europe Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 50. MEA Campylobacter Diagnostics, by Country USD Million (2016-2021)
  • Table 51. MEA Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 52. MEA Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 53. Middle East Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 54. Middle East Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 55. Africa Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 56. Africa Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 57. North America Campylobacter Diagnostics, by Country USD Million (2016-2021)
  • Table 58. North America Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 59. North America Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 60. United States Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 61. United States Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 62. Canada Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 63. Canada Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 64. Mexico Campylobacter Diagnostics, by Type USD Million (2016-2021)
  • Table 65. Mexico Campylobacter Diagnostics, by End User USD Million (2016-2021)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Campylobacter Diagnostics: by Type(USD Million)
  • Table 79. Campylobacter Diagnostics Culture-based Diagnosis , by Region USD Million (2022-2027)
  • Table 80. Campylobacter Diagnostics Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2022-2027)
  • Table 81. Campylobacter Diagnostics: by End User(USD Million)
  • Table 82. Campylobacter Diagnostics Hospitals , by Region USD Million (2022-2027)
  • Table 83. Campylobacter Diagnostics Private Laboratories , by Region USD Million (2022-2027)
  • Table 84. Campylobacter Diagnostics Independent Physician Chambers , by Region USD Million (2022-2027)
  • Table 85. Campylobacter Diagnostics Others , by Region USD Million (2022-2027)
  • Table 86. South America Campylobacter Diagnostics, by Country USD Million (2022-2027)
  • Table 87. South America Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 88. South America Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 89. Brazil Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 90. Brazil Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 91. Argentina Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 92. Argentina Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 93. Rest of South America Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 94. Rest of South America Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 95. Asia Pacific Campylobacter Diagnostics, by Country USD Million (2022-2027)
  • Table 96. Asia Pacific Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 97. Asia Pacific Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 98. China Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 99. China Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 100. Japan Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 101. Japan Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 102. India Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 103. India Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 104. South Korea Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 105. South Korea Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 106. Taiwan Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 107. Taiwan Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 108. Australia Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 109. Australia Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 110. Rest of Asia-Pacific Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 111. Rest of Asia-Pacific Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 112. Europe Campylobacter Diagnostics, by Country USD Million (2022-2027)
  • Table 113. Europe Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 114. Europe Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 115. Germany Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 116. Germany Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 117. France Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 118. France Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 119. Italy Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 120. Italy Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 121. United Kingdom Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 122. United Kingdom Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 123. Netherlands Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 124. Netherlands Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 125. Rest of Europe Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 126. Rest of Europe Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 127. MEA Campylobacter Diagnostics, by Country USD Million (2022-2027)
  • Table 128. MEA Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 129. MEA Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 130. Middle East Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 131. Middle East Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 132. Africa Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 133. Africa Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 134. North America Campylobacter Diagnostics, by Country USD Million (2022-2027)
  • Table 135. North America Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 136. North America Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 137. United States Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 138. United States Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 139. Canada Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 140. Canada Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 141. Mexico Campylobacter Diagnostics, by Type USD Million (2022-2027)
  • Table 142. Mexico Campylobacter Diagnostics, by End User USD Million (2022-2027)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Campylobacter Diagnostics: by Type USD Million (2016-2021)
  • Figure 5. Global Campylobacter Diagnostics: by End User USD Million (2016-2021)
  • Figure 6. South America Campylobacter Diagnostics Share (%), by Country
  • Figure 7. Asia Pacific Campylobacter Diagnostics Share (%), by Country
  • Figure 8. Europe Campylobacter Diagnostics Share (%), by Country
  • Figure 9. MEA Campylobacter Diagnostics Share (%), by Country
  • Figure 10. North America Campylobacter Diagnostics Share (%), by Country
  • Figure 11. Global Campylobacter Diagnostics share by Players 2021 (%)
  • Figure 12. Global Campylobacter Diagnostics share by Players (Top 3) 2021(%)
  • Figure 13. Global Campylobacter Diagnostics share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 16. Becton, Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 17. Meridian Bioscience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Meridian Bioscience, Inc. (United States) Revenue: by Geography 2021
  • Figure 19. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 21. BIOTECON Diagnostics (Germany) Revenue, Net Income and Gross profit
  • Figure 22. BIOTECON Diagnostics (Germany) Revenue: by Geography 2021
  • Figure 23. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 24. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 25. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Alere Inc. (United States) Revenue: by Geography 2021
  • Figure 27. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 28. QIAGEN (Germany) Revenue: by Geography 2021
  • Figure 29. Roche Molecular Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Roche Molecular Systems, Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Siemens Healthineers (Germany) Revenue: by Geography 2021
  • Figure 33. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Lonza (Switzerland) Revenue: by Geography 2021
  • Figure 35. ZeptoMetrix (United States) Revenue, Net Income and Gross profit
  • Figure 36. ZeptoMetrix (United States) Revenue: by Geography 2021
  • Figure 37. Sequenom (United States) Revenue, Net Income and Gross profit
  • Figure 38. Sequenom (United States) Revenue: by Geography 2021
  • Figure 39. Global Campylobacter Diagnostics: by Type USD Million (2022-2027)
  • Figure 40. Global Campylobacter Diagnostics: by End User USD Million (2022-2027)
  • Figure 41. South America Campylobacter Diagnostics Share (%), by Country
  • Figure 42. Asia Pacific Campylobacter Diagnostics Share (%), by Country
  • Figure 43. Europe Campylobacter Diagnostics Share (%), by Country
  • Figure 44. MEA Campylobacter Diagnostics Share (%), by Country
  • Figure 45. North America Campylobacter Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Becton, Dickinson and Company (United States)
  • Meridian Bioscience, Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • BIOTECON Diagnostics (Germany)
  • Agilent Technologies (United States)
  • Alere Inc. (United States)
  • QIAGEN (Germany)
  • Roche Molecular Systems, Inc. (United States)
  • Siemens Healthineers (Germany)
  • Lonza (Switzerland)
  • ZeptoMetrix (United States)
  • Sequenom (United States)
Select User Access Type

Key Highlights of Report


May 2023 200 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Campylobacter Diagnostics Market Quantitative research analysis
Global Campylobacter Diagnostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2027
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Low Awareness about Campylobacter Infection Diagnosis

Know More About Global Campylobacter Diagnostics Market Report?

Have a Query? Click Here

Other Related Reports

Brucellosis Comprehensive Study by Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, Others), Diagnosis (Serological Tests, Molecular Techniques, Bone Marrow ...
$ 3750
Carrion's Disease Comprehensive Study by Antibiotics (Chloramphenicol, Azithromycin, Erythromycin, Ciprofloxacin, Rifampin, Macrolides), Stages (Acute Phase, Chronic Phase), End User (Hospitals, Clin...
$ 3500
Campylobacteriosis Comprehensive Study by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Onl...
$ 3750
Bronchiolitis Comprehensive Study by Type (Viral Bronchiolitis, Bronchiolitis Obliterans), Treatment (Flu Shot, Corticosteroids, Intravenous Fluid Treatment, Others), End-users (Hospitals, Clinics, O...
$ 3650
Bacterial Meningitis Comprehensive Study by Type (Pneumococcal meningitis, Meningococcal meningitis, Listeria monocytogenes meningitis, Neonatal meningitis, Hemophilus (Hib) meningitis), Treatment (A...
$ 3750
Burkholderia Cepacia Infection Comprehensive Study by Application (Kids, Adults), Drug Type (Trimethoprim, Sulfamethoxazole, Trimethoprim and sulfamethoxazole, Meropenem, Minocycline, Cefepime, Tigec...
$ 3650